Bellevue Group Ag has filed its 13F form on August 14, 2025 for Q2 2025 where it was disclosed a total value porftolio of $4.39 Billion distributed in 175 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Argenx Se with a value of $315M, Ionis Pharmaceuticals Inc with a value of $310M, Neurocrine Biosciences Inc with a value of $229M, Alnylam Pharmaceuticals, Inc. with a value of $221M, and Abbott Laboratories with a value of $213M.

Examining the 13F form we can see an increase of $85.2M in the current position value, from $4.31B to 4.39B.

Bellevue Group Ag is based out at Kuesnacht, V8

Below you can find more details about Bellevue Group Ag portfolio as well as his latest detailed transactions.

Portfolio value $4.39 Billion
Healthcare: $4.39 Billion
ETFs: $3.77 Million
Technology: $608,000
Consumer Cyclical: $546,000
Communication Services: $426,000
Consumer Defensive: $202,000

Stock Holdings Table Market Cap. of $2 Billions to $10 Billions

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 175
  • Current Value $4.39 Billion
  • Prior Value $4.31 Billion
  • Filing
  • Period Q2 2025
  • Filing Date August 14, 2025
  • Form Type 13F-HR
  • Activity in Q2 2025
  • New Purchases 7 stocks
  • Additional Purchases 39 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 61 stocks
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.